OFF-LABEL USE OF INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR SALVAGE TREATMENT IN PROGRESSIVE THRESHOLD RETINOPATHY OF PREMATURITY
- 1 March 2008
- journal article
- case report
- Published by Wolters Kluwer Health in Retina
- Vol. 28 (3) , S13-S18
- https://doi.org/10.1097/iae.0b013e3181644ad2
Abstract
To report the short term anatomic response of intravitreal bevacizumab (Avastin, Genentech) as salvage treatment in progressive retinopathy of prematurity (ROP) in a small series of patients. The study included five eyes of three patients with progressive ROP despite peripheral laser ablation. Patients received intravitreal injections of bevacizumab (Avastin, Genentech). RetCam (Clarity Medical Systems, Inc., Pleasanton, CA) photography and ultrasonography were used to document effect. Three patients were transferred to the Bascom Palmer Eye Institute/Jackson Memorial Hospital for management of progressive ROP despite laser therapy at an outside facility. RetCam fundus photography and ultrasonography were used to document all cases. After informed consent was obtained from the parents, the patients received off-label intravitreal bevacizumab as salvage treatment. Repeat intravitreal injections of bevacizumab were utilized in several cases. The ROP stabilized allowing laser supplementation. There was varying development of tractional retinal detachments in several of the eyes but the ROP component quieted in all cases. Off-label use of bevacizumab appears to be useful as a salvage treatment for ROP when laser treatment is precluded. It improves dilation, quiets the disease when visibility is difficult, and temporizes the disease until laser can be supplemented.Keywords
This publication has 8 references indexed in Scilit:
- Intravitreal Bevacizumab (Avastin) in the Treatment of Proliferative Diabetic RetinopathyPublished by Elsevier ,2006
- INTRAVITREAL BEVACIZUMAB (AVASTIN) TREATMENT OF PROLIFERATIVE DIABETIC RETINOPATHY COMPLICATED BY VITREOUS HEMORRHAGERetina, 2006
- Pathogenesis of retinopathy of prematurityActa Paediatrica, 2002
- Vascular Endothelial Growth Factor and Hepatocyte Growth Factor Levels Are Differentially Elevated in Patients with Advanced Retinopathy of PrematurityThe American Journal of Pathology, 2000
- Current Incidence of Retinopathy of Prematurity, 1989–1997Pediatrics, 1999
- Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucomaOphthalmology, 1998
- Levels of vascular endothelial growth factor are elevated in the vitreous of patients with subretinal neovascularisation.British Journal of Ophthalmology, 1996
- Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurityNature Medicine, 1995